Evans, Elizabeth,Smith, Ernest S.,Zauderer, Maurice
申请号：
AU2018237549
公开号：
AU2018237549A1
申请日:
2018.03.14
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof. The disclosure further provides a pharmaceutical composition comprising the combination therapy.
